The Effect of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors on Circulating Endothelial Progenitor Cells in Patients with Cardiovascular Disease.

Osnat Itzhaki Ben ZadokAviv MagerDorit Leshem-LevEli LevRan KornowskiAlon Eisen

Published in: Cardiovascular drugs and therapy (2021)

Patients with CVD treated with PCSK9i demonstrate higher levels of active cEPCs, reflecting the promotion of endothelial repair. These findings may represent a novel mechanism of action of PCSK9i.

Keyphrases

low density lipoprotein
cardiovascular disease
endothelial cells
type diabetes
cardiovascular risk factors
metabolic syndrome
newly diagnosed
cardiovascular events